Advertisement
Paper| Volume 37, ISSUE 6, P639-649, March 15, 1985

Whole blood clot lysis: In vitro modulation by activated protein C

DOI:https://doi.org/10.1016/0049-3848(85)90193-8
Whole blood clot lysis: In vitro modulation by activated protein C
Previous ArticleFibrinogen fragment D is a recognition site for release-related platelet aggregation
Next ArticleThe role of fibronectin in factor VIII/von Willebrand factor cryoprecipitation
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Lysis of clots prepared from native or citrated whole blood as measured by release of 125I fibrinogen degradation products was 10% or less at 20 hours. Lysis of these clots was accelerated by activated protein C in a dose-dependent manner (0.1 to 20 μg/ml) from less than 10% to 60–80% at 20 hours. Lysis of clots prepared from native or citrated platelet poor plasma across the same concentration range of activated protein C was less than 15%. Gla-domainless activated protein C was equally effective in accelerating clot lysis whereas DIP-activated protein C or factor Xa did not accelerate clot lysis. This suggested that this action of activated protein C was enzymatic and this this action was limited to protein C among the vitamin K dependent proteins.
      The unresponsiveness of platelet poor plasma to activated protein C was completely restored to that of whole blood by addition of mononuclear leukocytes. Addition of red corpuscles or platelets Math Eq had no effect on this response, while addition of polymorphonuclear leukocytes partially restored this response. Addition of metabolic inhibitors 2-deoxyglucose and oligomycin inhibited the response of whole blood and of plasma-mononuclear leukocytes to activated protein C. Reconstitution studies of platelet poor plasma made deficient in plasminogen activator and plasminogen showed that accelerated clot lysis produced by mononuclear leukocytes and activated protein C required the presence of plasminogen. We concluded, therefore, that activated protein C accelerates whole blood or plasma-leukoycte clot lysis by modulating activation of the plasminogen system by metabolically active leukocytes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • von Kaulla K.M.
        • von Kaulla E.
        Remarks on the euglobulin lysis time.
        in: Progress in Chemical Fibrinolysis and Thrombolysis.Vol. 1. Raven Press, New York1975: 121
        • Fearnley G.R.
        • Balmforth G.
        • Fearnley E.
        Evidence of diurnal fibrinolytic rhythm, with a simple method of measuring natural fibrinolysis.
        Clin. Sci. 1957; 16: 645
        • Kaplan A.P.
        • Meier H.L.
        • Mandle R.
        The Hagemen factor dependent pathways of coagulation, fibrinolysis, and kinin-generation.
        Semin. Thromb. Hemostas. 1976; 3: 1
        • Walther P.J.
        • Steinmen H.M.
        • Hill R.L.
        • McKee P.A.
        Activation of human plasminogen by urokinase.
        in: Partial characterization of preactivation peptide. J. Biol. Chem.249. 1974: 1173
        • Tillett W.S.
        • Garner R.L.
        The fibrinolytic activity of hemolytic streptococci.
        J. Exp. Med. 1933; 58: 485
        • Sherry S.
        • Lindemeyer R.I.
        • Fletcher A.P.
        • Alkjaersig N.
        Studies on enhanced fibrinolytic activity in man.
        J. Clin. Invest. 1959; 38: 810
        • Sakata Y
        • Aoki N.
        Significance of crosslinking of α2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
        J. Clin. Invest. 1982; 69: 536
        • Wiman B.
        • Chmielewska J.
        • Rinby M.
        Inactivation of tissue plasminogen activator in plasma.
        J. Biol. Chem. 1984; 259: 3644
        • Moroz L.A.
        Mini-plasminogen: A mechanism for leukocyte modulation of plasminogen activation by urokinase.
        Blood. 1981; 58: 97
        • Plow E.F.
        Leukocyte elastase release during blood coagulation.
        in: A potential mechanism for activation of the alternative fibrinolytic pathway. J. Clin. Invest.69. 1982: 564
        • Lijnen H.R.
        • Collen D.
        Interaction of plasminogen activators and inhibitors with plasminogen and fibrin.
        Semin. Thromb. Hemostas. 1982; 8: 2
        • Esmon C.T.
        • Owen W.G.
        Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.
        in: Proc. Natl. Acad. Sci. USA. 78. 1981: 2249
        • Comp P.C.
        • Jacocks R.M.
        • Ferrell G.L.
        • Esmon C.T.
        Activation of protein C in vivo.
        J. Clin. Invest. 1982; 70: 127
        • Taylor F.B.
        • Esmon C.T.
        • Carroll R.C.
        • Lockhart M.L.
        Adherent mononuclear cells and activated protein C.
        (APC). Thromb. Haemost. 1981; 46 (Abstr): 178
        • Zolton R.P.
        • Seegers W.H.
        Autoprothrombin II-A: Thrombin removal and mechanism of induction of fibrinolysis.
        Thromb. Res. 1973; 3: 23
        • Lockhart M.S.
        • Lee E.T.
        • Taylor Jr., F.B.
        Observation on optimal conditions for lysis of whole blood clots and use of this assay as a screening assay in clinical investigation.
        Thromb. Res. 1982; 28: 625
        • Beutler E.
        • West C.
        • Blume K.G.
        The removal of leukocytes and platelet from whole blood.
        J. Lab. Clin. Med. 1976; 88: 328
        • Johnston Jr., R.B.
        • Klemperer M.R.
        • Alper C.A.
        • Rosen F.S.
        The enhancement of bacterial phagocytosis by serum.
        in: The role of complement components and two cofactors. J. Exp. Med.129. 1969: 1275
        • English D.
        • Anderson B.R.
        Single-step separation of red blood cells, granulocytes, and mononuclear leukocytes on discontinuous density gradients of ficoll-hypaque.
        J. Immunol. Methods. 1974; 5: 249
        • Schwartz B.W.
        • Edgington T.S.
        Immune complex induced human monocyte procoagulant activity. I. A rapid unidirectional lymphocytic instructed pathway.
        J. Exp. Med. 1981; 154: 892
        • Carroll R.C.
        • Taylor F.B.
        • Gerrard J.M.
        • Radcliffe R.D.
        Plasminogen, plasminogen activator and platelets in the regulation of clot lysis (reconstitution and patient studies.
        J. Lab. Clin. Med. 1982; 100: 986
        • Comp P.C.
        • Jacocks R.M.
        A specific circulating plasminogen activator or class of activators elevated in conditions associated with increased fibrinolytic activity.
        J. Lab. Clin. Med. 1981; 97: 637
        • Deutsch D.G.
        • Mertz E.T.
        Plasminogen: Purification from human plasma by affinity chromatography.
        Science. 1970; 170: 1095
        • Radcliffe R.
        • Heinze T.
        Isolation of plasminogen activator from human plasma by chromatography on lysine-sepharose.
        Arch. Biochem. Biophys. 1978; 189: 185
        • Wallen P.
        Chemistry of plasminogen and plasminogen activation.
        in: Progress in Chemical Fibrinolysis and Thrombolysis. Vol. 3. Raven Press, New York1978: 167-181
        • Granelli-Piperno
        • Reich E.A.
        A study of protein inhibitor complexes biological fluid.
        J. Exp. Med. 1978; 148: 223-234
        • Walker F.J.
        • Sexton P.W.
        • Esmon C.T.
        The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V.
        Biochim. Biophys. Acta. 1979; 371: 333
        • Stenflo J.
        A new vitamin K dependent protein.
        in: Purification from bovine plasma and preliminary characterization. J. Biol. Chem.251. 1976: 355
        • Esmon N.L.
        • Debault L.E.
        • Esmon C.T.
        Proteolytic formation and properties of Gla-domainless protein C.
        J. Biol. Chem. 1981; 258: 5548
        • Johnson A.J.
        • Esmon N.L.
        • Lade T.M.
        • Esmon C.T.
        Structural changes required for activation of protein C are induced by Ca2+ binding to a high affinity site that does not contain γ-carboxyglutamic acid.
        J. Biol. Chem. 1983; 258: 5554
        • Skogen W.F.
        The activation of coagulation factor X by the factor X activator isolated from the venom of Vipera Russelli.
        in: Ph.D. Thesis. University of Oklahoma Health Sciences Center, Dept. Biochemistry, 1983
        • Owen W.G.
        • Esmon C.T.
        • Jackson C.M.
        The conversion of prothrombin to thrombin. I. Characterization of the reaction products formed during the activation of bovine prothrombin.
        J. Biol. Chem. 1974; 249: 594
        • Colucci M.
        • Stassen J.M.
        • Collen D.
        Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys.
        J. Clin. Invest. 1984; 74: 200
        • Esmon C.T.
        The function of protein C.
        in: Contemporary Hematology/ Oncology.Vol. 3. Plenum, New York1983

      Article info

      Publication history

      Accepted: December 18, 1984
      Received: October 16, 1984

      Identification

      DOI: https://doi.org/10.1016/0049-3848(85)90193-8

      Copyright

      © 1985 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX